Cinzia Pellizzoni

768 total citations
18 papers, 614 citations indexed

About

Cinzia Pellizzoni is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Cinzia Pellizzoni has authored 18 papers receiving a total of 614 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Pharmacology and 5 papers in Oncology. Recurrent topics in Cinzia Pellizzoni's work include Pharmacogenetics and Drug Metabolism (4 papers), Cancer therapeutics and mechanisms (3 papers) and Pharmacological Effects and Toxicity Studies (3 papers). Cinzia Pellizzoni is often cited by papers focused on Pharmacogenetics and Drug Metabolism (4 papers), Cancer therapeutics and mechanisms (3 papers) and Pharmacological Effects and Toxicity Studies (3 papers). Cinzia Pellizzoni collaborates with scholars based in Italy, United States and Belgium. Cinzia Pellizzoni's co-authors include Italo Poggesi, E. Frigerio, M. Strolin Benedetti, M. G. Castelli, Enrico Pesenti, R. Spinelli, Daniela Fraier, Joseph C. Fleishaker, Roland d'Argy and Antonino Suarato and has published in prestigious journals such as Journal of Controlled Release, British Journal of Cancer and Clinical Pharmacology & Therapeutics.

In The Last Decade

Cinzia Pellizzoni

18 papers receiving 591 citations

Peers

Cinzia Pellizzoni

BIOMA

ONCOL

PHARM

Guofei Li China

Mila Renftel Sweden

Yuyan Li China

E. Frigerio Italy

Cecilia Allievi Italy

A.K. Babbar India

Guoguang Chen China

Chi Meng China

Wan Xu China

Guofei Li China

Cinzia Pellizzoni

186 ×0.7

110 ×0.6

BIOMA

84 ×0.6

ONCOL

73 ×0.6

PHARM

70 ×0.7

Citations per year, relative to Cinzia Pellizzoni Cinzia Pellizzoni (= 1×) peers Guofei Li

Countries citing papers authored by Cinzia Pellizzoni

Since Specialization

Citations

This map shows the geographic impact of Cinzia Pellizzoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cinzia Pellizzoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cinzia Pellizzoni more than expected).

Fields of papers citing papers by Cinzia Pellizzoni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cinzia Pellizzoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cinzia Pellizzoni. The network helps show where Cinzia Pellizzoni may publish in the future.

Co-authorship network of co-authors of Cinzia Pellizzoni

This figure shows the co-authorship network connecting the top 25 collaborators of Cinzia Pellizzoni. A scholar is included among the top collaborators of Cinzia Pellizzoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cinzia Pellizzoni. Cinzia Pellizzoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Fiorentini, Francesco, Massimiliano Germani, Cinzia Pellizzoni, et al.. (2023). Population pharmacokinetic–pharmacodynamic analysis of givinostat. Expert Opinion on Drug Metabolism & Toxicology. 19(4). 229–238. 2 indexed citations

Massard, Christophe, Jean‐Charles Soria, Alan Anthoney, et al.. (2011). A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors. Cell Cycle. 10(6). 963–970. 44 indexed citations

Rocchetti, Maurizio, Italo Poggesi, Massimiliano Germani, et al.. (2005). A Pharmacokinetic‐Pharmacodynamic Model for Predicting Tumour Growth Inhibition in Mice: A Useful Tool in Oncology Drug Development. Basic & Clinical Pharmacology & Toxicology. 96(3). 265–268. 24 indexed citations

Bissett, D., J Cassidy, Johann S. de Bono, et al.. (2004). Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). British Journal of Cancer. 91(1). 50–55. 92 indexed citations

Rocchetti, Maria Teresa, Italo Poggesi, Massimiliano Germani, et al.. (2004). A PK-PD model for predicting tumor growth inhibition in mice: a useful tool in oncology drug development. 1 indexed citations

Kelly, William Kevin, Andrew X. Zhu, Howard I. Scher, et al.. (2003). Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.. PubMed. 9(6). 2098–107. 14 indexed citations

Kesteren, Charlotte van, Hilde Rosing, Jan A. Lieverst, et al.. (2002). A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. British Journal of Cancer. 87(6). 608–614. 87 indexed citations

Caiolfa, Valeria R., Moreno Zamai, Antonio Fiorino, et al.. (2000). Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. Journal of Controlled Release. 65(1-2). 105–119. 135 indexed citations

Poggesi, Italo, Cinzia Pellizzoni, & Joseph C. Fleishaker. (2000). Pharmacokinetics of reboxetine in elderly patients with depressive disorders. International Journal of Clinical Pharmacology and Therapeutics. 38(5). 254–259. 9 indexed citations

10.

Denolle, Thierry, Cinzia Pellizzoni, M.G. Jannuzzo, & Italo Poggesi. (1999). Hemodynamic effects of reboxetine in healthy male volunteers*. Clinical Pharmacology & Therapeutics. 66(3). 282–287. 20 indexed citations

11.

Fleishaker, Joseph C., et al.. (1999). Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics. Biopharmaceutics & Drug Disposition. 20(1). 53–57. 33 indexed citations

12.

Breda, Massimo, M. Strolin Benedetti, Massimo Bani, et al.. (1999). EFFECT OF RIFABUTIN ON ETHAMBUTOL PHARMACOKINETICS IN HEALTHY VOLUNTEERS. Pharmacological Research. 40(4). 351–356. 11 indexed citations

13.

Frigerio, E., et al.. (1997). Pharmacokinetics of reboxetine enantiomers in the dog. Chirality. 9(3). 303–306. 11 indexed citations

14.

Pellizzoni, Cinzia, et al.. (1996). PHARMACOKINETICS OF REBOXETINE IN HEALTHY VOLUNTEERS. SINGLE AGAINST REPEATED ORAL DOSES AND LACK OF ENZYMATIC ALTERATIONS. Biopharmaceutics & Drug Disposition. 17(7). 623–633. 20 indexed citations

15.

Benedetti, M. Strolin, et al.. (1995). Stereoselective and species‐dependent kinetics of reboxetine in mouse and rat. Chirality. 7(4). 285–289. 47 indexed citations

16.

Pellizzoni, Cinzia, Annamaria Berardi, M. G. Castelli, et al.. (1995). Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharmaceutics & Drug Disposition. 16(6). 443–460. 51 indexed citations

17.

Jannuzzo, M.G., M. Ryde, Ola Rönn, et al.. (1995). P-2-77 Pharmacokinetics of reboxetine in healthy volunteers of different ages. European Neuropsychopharmacology. 5(3). 300–300. 4 indexed citations

18.

Pellizzoni, Cinzia, M. Strolin Benedetti, Italo Poggesi, et al.. (1995). Pharmacokinetics of reboxetine in healthy volunteers: relative bioavailability and food effect. Pharmacological Research. 31. 41–41. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact